Targeted immunotherapy for HER2-low breast cancer with 17p loss

Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study

(2020) Shanu Modi et al.   JOURNAL OF CLINICAL ONCOLOGY

In vitro mechanistic studies on α-amanitin and its putative antidotes

(2020) Daniela Ferreira Rodrigues et al.   ARCHIVES OF TOXICOLOGY

Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors

(2020) Lorenzo Galluzzi et al.   Nature Reviews Clinical Oncology

Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer

(2019) Jiangsheng Xu et al.   Nature Nanotechnology

Immune-checkpoint inhibition for metastatic triple-negative breast cancer: safety first?

(2019) Nina D’Abreo et al.   Nature Reviews Clinical Oncology

NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+

(2019) Louis Fehrenbacher et al.   JOURNAL OF CLINICAL ONCOLOGY

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

(2018) Peter Schmid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Heterozygous deletion of chromosome 17p renders prostate cancer vulnerable to inhibition of RNA polymerase II

(2018) Yujing Li et al.   Nature Communications

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer

(2017) Aditya Bardia et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial

(2017) Véronique Diéras et al.   LANCET ONCOLOGY

Strategies and challenges for the next generation of antibody–drug conjugates

(2017) Alain Beck et al.   NATURE REVIEWS DRUG DISCOVERY

Antibody–drug conjugates for cancer therapy

(2016) Anish Thomas et al.   LANCET ONCOLOGY

Deletions linked to TP53 loss drive cancer through p53-independent mechanisms

(2016) Yu Liu et al.   NATURE

Vaccination with Necroptotic Cancer Cells Induces Efficient Anti-tumor Immunity

(2016) Tania Løve Aaes et al.   Cell Reports

TP53 loss creates therapeutic vulnerability in colorectal cancer

(2015) Yunhua Liu et al.   NATURE

limma powers differential expression analyses for RNA-sequencing and microarray studies

(2015) Matthew E. Ritchie et al.   NUCLEIC ACIDS RESEARCH

Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

(2014) Antonella Sistigu et al.   NATURE MEDICINE

Impact of Tumor HER2/ERBB2 Expression Level on HER2-Targeted Liposomal Doxorubicin-Mediated Drug Delivery: Multiple Low-Affinity Interactions Lead to a Threshold Effect

(2013) B. S. Hendriks et al.   MOLECULAR CANCER THERAPEUTICS

RNA-Guided Human Genome Engineering via Cas9

(2013) P. Mali et al.   SCIENCE

Multiplex Genome Engineering Using CRISPR/Cas Systems

(2013) L. Cong et al.   SCIENCE

Immunogenic Cell Death in Cancer Therapy

(2012) Guido Kroemer et al.   Annual Review of Immunology

Therapeutic Potential of Amanitin-Conjugated Anti-Epithelial Cell Adhesion Molecule Monoclonal Antibody Against Pancreatic Carcinoma

(2012) Gerhard Moldenhauer et al.   JNCI-Journal of the National Cancer Institute

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

(2012) Sunil Verma et al.   NEW ENGLAND JOURNAL OF MEDICINE

Circos: An information aesthetic for comparative genomics

(2009) M. Krzywinski et al.   GENOME RESEARCH

Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs

(2008) Jagath R. Junutula et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index

(2008) Jagath R Junutula et al.   NATURE BIOTECHNOLOGY

Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer

(2008) Gabriella Mariani et al.   Nature clinical practice. Oncology